• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
YUAN Ni, TIAN Tingting, ZHANG Haijun, WANG Yong. Major routes for orphan drugs to be incorporated into the reimbursement system of UK and the enlightenment to China[J]. Journal of China Pharmaceutical University, 2019, 50(1): 113-119. DOI: 10.11665/j.issn.1000-5048.20190116
Citation: YUAN Ni, TIAN Tingting, ZHANG Haijun, WANG Yong. Major routes for orphan drugs to be incorporated into the reimbursement system of UK and the enlightenment to China[J]. Journal of China Pharmaceutical University, 2019, 50(1): 113-119. DOI: 10.11665/j.issn.1000-5048.20190116

Major routes for orphan drugs to be incorporated into the reimbursement system of UK and the enlightenment to China

More Information
  • In order to provide enlightening experience for the establishment of reasonable and diversified orphan drugs into the reimbursement system in China, the official websites of the National Institute for Health and Care Excellence(NICE)and the National Health Service(NHS)in the UK were inspected, collecting and summarizing the relevant documents, on the inclusion of orphan drugs into the reimbursement system. Relevant literatures were analyzed with theoretical studies on the accessibility of medicines for patients with rare diseases. In the NHS system, the inclusion of orphan drugs into the reimbursement system in the UK can be achieved mainly through seven routes, with three routes that are evaluated by NICE(MTA, STA and HST)and four are directly managed by the NHS(specialized commissioning, CDF, IFRs, CtE). Through the analysis of the inclusion of orphan drugs into the reimbursement system and the various problems in the UK, we have found some enlightening experience for the establishment of the reimbursement system for orphan drugs in China.
  • [1]
    Gong SW.Study of management strategies of improving access to orphan drugs in china(促进我国罕见病患者药品可及性的管理策略研究)[D].Wuhan:Huazhong University of Science and Technology,2008.
    [2]
    Sui BY,Qi XR.Experience from translation mechanisms in the NICE health technology assessment to NHS decision making[J].Chin J Health Policy(中国卫生政策研究),2015,8(7):74-78.
    [3]
    National Institute for Health and Care Excellence.Guide to the processes of technology appraisal2014[R].London:NICE,2014.
    [4]
    National Institute for Health and Care Excellence.Summary of decisions[EB/OL].[2018-03-19] .https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice technology-appraisal-guidance/summary-of-decisions.
    [5]
    National Institute for Health and Care Excellence.Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease[R].London:NICE,2017.
    [6]
    National Institute for Health and Care Excellence.Summary of decisions[EB/OL].[2018-05-17] .https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/summary-of-decisions.
    [7]
    National Institute for Health and Care Excellence.Guide to the processes of technology appraisal 2014[R].London:NICE,2014.
    [8]
    National Institute for Health and Care Excellence.Eltrombopag for treating chronic immune(idiopathic)thrombocytopenic purpura[R].London:NICE,2013.
    [9]
    National Institute for Health and Care Excellence.Interim process and methods of the highly specialized technologies programme[R].London:NICE,2017.
    [10]
    National Health Service.Specialized services[EB/OL].[2018-05-18] .https://www.england.nhs.uk/commissioning/spec-services/.
    [11]
    NHS England.Implementation plan for the uk strategy for rare diseases[R].England:NHS England,2018.
    [12]
    NHS England Cancer Drugs Fund Team.Appraisal and funding of cancer drugs from July 2016(including the new Cancer Drugs Fund)- A new deal for patients,taxpayers and industry[R].England:NHS England,2016.
    [13]
    NHS England Cancer Drugs Fund Team.National cancer drugs fund list[R].England:NHS England,2016.
    [14]
    National Institute for Health and Care Excellence.Consultation comments on the draft remit and draft scope for the technology appraisal of cabozantinib for previously treated advanced renal cell carcinoma[R].England:NICE.
    [15]
    Specialized Commissioning Team.Standard operating procedures:individual funding requests[R].England:NHS England,2017.
    [16]
    NHS England.Methods:Commissioning through Evaluation[R].England:NHS England,2017.
    [17]
    National Health Service.Commissioning through evaluation[EB/OL].[2018-05-20] .https://www.england.nhs.uk/commissioning/spec-services/npc-crg/comm-eval/.
  • Related Articles

    [1]YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. Journal of China Pharmaceutical University, 2024, 55(5): 590-602. DOI: 10.11665/j.issn.1000-5048.2024052202
    [2]LUO Xuelian, WU Chengsheng, ZHA Cheng, LIU Sheng. Research progress and prospects of implantable drug delivery systems for postoperative tumor therapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 538-547. DOI: 10.11665/j.issn.1000-5048.2024040901
    [3]WANG Shihao, LIU Lifeng, DING Yang, LI Suxin. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 522-529. DOI: 10.11665/j.issn.1000-5048.2024011902
    [4]YU Jiayu, LIN Zezhi, CAO Wei, ZHANG Jianjun, WEI Yuanfeng, GAO Yuan, QIAN Shuai. Research progress of bio-metal organic frameworks in drug delivery system[J]. Journal of China Pharmaceutical University, 2023, 54(1): 23-33. DOI: 10.11665/j.issn.1000-5048.20221111003
    [5]ZHOU Yeshu, WANG Yanmei, ZHANG Beiyuan, WU Shuaicong, YANG Lei, YIN Lifang. Research progress of inorganic nanomaterials in drug delivery system[J]. Journal of China Pharmaceutical University, 2020, 51(4): 394-405. DOI: 10.11665/j.issn.1000-5048.20200403
    [6]LI Haoxian, LIN Huaqing, CHEN Jingwen, WANG Liyuan. Research progress of carbon nanomaterials in cancer drug delivery[J]. Journal of China Pharmaceutical University, 2019, 50(1): 100-106. DOI: 10.11665/j.issn.1000-5048.20190114
    [7]FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302
    [8]CHEN Xing, KANG Yang, WU Jun. Advances in biodegradable functional polymers based protein drug delivery system[J]. Journal of China Pharmaceutical University, 2017, 48(2): 142-149. DOI: 10.11665/j.issn.1000-5048.20170203
    [9]WANG Yazhe, ZHOU Jianping, DING Yang, WANG Wei. Advances in research of biomimetic drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(3): 267-273. DOI: 10.11665/j.issn.1000-5048.20140303
    [10]TANG Yue, KE Xue. Advances of mesoporous silica nanoparticles as drug delivery system[J]. Journal of China Pharmaceutical University, 2012, 43(6): 567-572.
  • Cited by

    Periodical cited type(0)

    Other cited types(2)

Catalog

    Article views (831) PDF downloads (1563) Cited by(2)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return